<DOC>
	<DOCNO>NCT01994031</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) paclitaxel liposome injection compare pharmacokinetic character paclitaxel liposome injection paclitaxel injection value effectiveness cancer treatment .</brief_summary>
	<brief_title>Dose Escalation Pharmacokinetic Study Paclitaxel Liposome Injection Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>patient willing sign Investigational Review Board ( IRB ) approve write informed consent document patient age : 18 year 75years patient must histologically confirm solid tumor patient must uncurable unresectable solid tumor advance stage patient must Eastern Cooperative Oncology Group ( ECOG ) performance status 01 patient must life expectancy least 12 week patient must least one lesion measurable accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.0 patient must progress recurrence least one chemotherapy regimen advance stage patient must adequate marrow , hepatic renal function : define ANC≥2.0 × 109/L，PLT ≥10 ×109/dL , Hb ≥ 9g/dL ; GOT/GPT≤2.5×ULN；Toltle bilirubin ≤1.5×ULN ; Serum creatinine ≤1.5×ULN Creatinine clearance≥40ml/min ( accord CockcroftGault； patient must leave ventricular ejection fraction ( LVEF ) ≥50 % confirm ultrasonic heart scan woman must negative pregnancy test ; woman men must agree use adequate contraception patient must non received antitumor therapy , include chemotherapy , radiotherapy , hormonal therapy , biological therapy , immunotherapy investigational agent within 4 week prior start study patient must non preexist toxity prior antitumor therapy ( any≥ grade 2 , any≥1 peripheral neuropathy , exclude alopecia ) patient must non uncontrolled cerebral metastasis patient must non uncontrolled heart illness include , limited , ongoing symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , arterial hypertension ( ≥180/110 ) , heart failure myocardial infarction within 6 month prior start study Patient must history malignancy tumor except follow : adequately treat localized basal cell squamous cell carcinoma skin , carcinoma situ cervix least 5 year patient must non serious illness include , limited hepatic , renal , respiratory uncontrolled diabetes mellitus patient must non psychiatric illness/social situation would limit compliance study requirement . patient must non active uncontrolled infection include , limited tuberculosis , HIV , HBV , HCV Patient must non receive antitumor agent patient must non pregnant and/or breastfeed patient must non receive protease inhibitor , inhibitor CYP3A4 , antifungal agent induce agent CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>paclitaxel liposome injection</keyword>
	<keyword>paclitaxel</keyword>
</DOC>